German biotech MorphoSys Inc., the latest firm to benefit from big pharma's burgeoning interest in antibodies, signed its, by far, largest deal to date, partnering with Novartis AG in a 10-year discovery and development alliance that could be worth more than $1 billion. (BioWorld Today)
German biotech MorphoSys Inc., the latest firm to benefit from big pharma's burgeoning interest in antibodies, signed its, by far, largest deal to date, partnering with Novartis AG in a 10-year discovery and development alliance that could be worth more than $1 billion. (BioWorld Today)
Vertex Pharmaceuticals Inc.'s collaboration with Merck & Co. Inc. to develop Aurora kinase inhibitors in cancer encountered a bump in the road after preliminary safety data indicated a potential cardiovascular effect in one patient treated with lead candidate, MK-0457 (VX-680). (BioWorld Today)
